Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) commences share repurchases on December 12, 2018 under the program mandated by the shareholders in the Extraordinary General Meeting held on November 6, 2018. As per the mandate, the company is authorized to repurchase up to a maximum of 5,555,500 class A shares, representing 0.46% of the issued share capital, for not more than CNY 100 million. The shares will be purchased at a price not exceeding CNY 17.9 per share. The purpose of repurchase program is implementation of equity incentive, ESOP and reduce company's registered capital. The repurchased shares will be cancelled. The repurchase program is valid for a period of 12 months from shareholders' approval.